Disturbed calcium-vitamin D metabolism in patients on anti-epileptic drugs

Dabla PK*, Sharma S and Puri V

1Department of Biochemistry, G.B Pant Institute of Postgraduate Medical Education & Research, Associated to Maulana Azad Medical College, New Delhi, India
2Department of Biochemistry, Chacha Nehru Bal Chikitsalya, Associated to Maulana Azad Medical College, New Delhi, India
3Department of Neurology, G.B Pant Institute of Postgraduate Medical Education & Research, Associated to Maulana Azad Medical College, New Delhi, India

Abstract

Introduction: Epilepsy is a common chronic neurological disorder, usually requiring long term treatment with anti-epileptic drugs (AEDs). There is paucity in data in relation to the effect of AED on calcium metabolism in North India. In view of this the present study was undertaken to assess the effect of AED on calcium metabolism.

Methods: The present cross-sectional study included epileptic patients of both sex attending the neurology OPD & IPD clinics. Patients were divided into three groups: - group 1 included patients on monotherapy receiving 1 AED, group 2 on dual therapy receiving 2 AED and group 3 on polytherapy receiving>2 AED. Serum analysis of total calcium, phosphorus, alkaline phosphorus, ionised calcium & vitamin D levels were conducted. The data between the groups was analyzed by using 1 way analysis of variance (ANOVA).

Results: The study included 150 patients in which 50 patients each belonged to groups 1, 2 and 3 respectively. 60% patients were male. 86 patients had generalised epilepsy and 64 suffered from partial seizures. 42% of the patients were on AED treatment for>5 years. Serum levels of calcium and vitamin D were significantly decreased (p<0.001 and p<0.05 respectively) in the polytherapy group in comparison to the mono and dual therapy groups. On the other hand, alkaline phosphatase & phosphorus levels were significantly increased in the polytherapy group (p<0.001).

Conclusion: Hypovitaminosis was commonly observed in the patients on AED, even at sub-therapeutic serum levels of the drug.

Introduction

Epilepsy is a neurological disorder characterised by abnormal brain activity, causing seizures or periods of unusual behaviour, sensations and sometimes loss of awareness. The disease affects males and females of all races, ethnic background and ages. Transient symptoms can occur, such as loss of awareness or consciousness and disturbances of movement, sensation (including vision, hearing, and taste), mood, or mental function [1]. 70 million individuals are affected with epilepsy all over the world and nearly 12 million reside in India. The overall prevalence in India approximates 3 to 11.9 per 1000 population [2]. Anti epileptic drugs (AEDs) are the first choice of treatment for these individuals. However more than 50% of epileptics on AED develop bone abnormalities [3]. Cytochrome P-450 (CYP450) isoenzymes are induced by AEDs especially the classic AEDs such as benzodiazepines, carbamezepine, phenytoin, phenobarbital and valproic acid. The induction of these CYP-450 enzymes may lead to vitamin D deficiency, hypercalcemia, and increased risk of fractures, altered bone turnover which can lead to impaired bone mineral density [3]. Apart from AEDs, glucocorticoids, aromatase inhibitors, and anti-androgenic drugs are also associated with increased risk of osteoporosis [4]. If these drugs are used with AEDs, the risk of a decrease in bone density is highly increased. Recent studies have demonstrated that the awareness of neurologists regarding the effects of AEDs on bone density is low (28%). It has been reported that a small number of pediatric neurologists (9%) and adult neurologists (7%) prophylactically prescribe calcium and vitamin D together with AEDs [5]. The negative effects of AEDs on bone density are complex, and their mechanism has not been fully understood. Both enzyme-inducing and non-inducing AEDs may cause abnormalities in bone metabolism [6,7]. There are very few studies in the Indian sub-continent evaluating vitamin D and calcium profile in epileptic patients with different treatment modalities. The aim of the present study was to therefore investigate the calcium metabolism in epilepsy patients who were on mono, dual and polytherapy anti-epileptic drug regime.

Materials and methods

The present cross-sectional study included consented epileptic patients of both sex attending the epilepsy clinic, admitted to the neurology ward of GIPMER New Delhi. It was conducted between period of Jan to Dec 2017. Patients with co morbid illness such as gastrointestinal disease, chronic liver disease, kidney disease or those on calcium-vitamin D supplementation were excluded from the study. Patients were divided into three groups: - group 1 included patients on monotherapy receiving 1 AED, group 2 on dual therapy receiving 2 AED

*Correspondence to: Dr. Pradeep Kumar Dabla, MD, Professor, Department of Biochemistry, G.B Pant Institute of Postgraduate Medical Education and Research, Associated to Maulana Azad Medical College, New Delhi, India, E-mail: pradeep_dabla@gmail.com

Key words: anti-epileptic drugs, calcium metabolism, vitamin D, epilepsy

Received: December 23, 2019; Accepted: January 03, 2020; Published: January 06, 2020
and group 3 patients on polytherapy receiving >2 AED. 4-5 ml of blood sample was collected in plain red vacutainer under aseptic conditions for analysing total calcium, phosphorus, alkaline phosphorus, ionised calcium, Vitamin D and Parathyroid hormone (PTH) levels. Fresh, clear, and nonhemolyzed samples were used. Routine tests were analyzed by Roche Cobas c501 autoanalyzer. The serum was separated and stored at -20°C until batch analysis for the estimation of 25(OH) hydroxyvitamin D (25(OH) D), PTH with Roche immunoassay autoanalyzer Cobas e411 using electrochemiluminescence technique. The minimum detection limit for PTH was 1 pg/ml (reporting reference interval 15-65 pg/ml) and for 25(OH) D was 5 ng/ml with the analytical measurement range of 3-70 ng/ml. The preferred level for 25(OH) D is recommended to be ≥30 ng/ml. In this protocol, vitamin D deficiency was defined by serum levels of 25(OH) D <20 ng/ml. Insufficiency was defined as 25(OH) D between 20 and 30 ng/ml. Data was expressed as mean±standard deviation values. The data between the groups was analyzed by using 1-way analysis of variance (ANOVA). A p value of <0.05 was accepted as statistically significant.

Results

The present cross-sectional study included 150 patients in which 50 patients each belonged to groups1, 2 and 3 respectively. Patients in our study were associated with age group of 15-35 years with male:female ratio of 1.4:1. Mean age of onset of seizures in the study group was 19.18±7.43 yrs. 86 patients had generalised epilepsy and 64 suffered from partial seizures. Table 1 shows 42% of the patients were on AED treatment with seizures duration for more than 5 years whereas the mean duration of seizures was highest in polytherapy group as 5.86±2.31 years in Table 4. With reference to Table 2 showing biochemical measurements, calcium and phosphorus levels were found to be significantly decreased in patients on polytherapy in comparison to those on mono and dual therapy (p=0.000 respectively). Similarly, Vitamin D levels were found to be the lowest in patients on polytherapy (p=0.000). On the other hand, levels of Alkaline Phosphatase & PTH were found to be elevated in the polytherapy group (p=0.000) as shown in Table 2.

25 (OH) Vitamin D deficiency (< 20 ng/mL) was observed in 72% patients on monotherapy (n=36), in 86% patients on dual therapy (n=43) and 96% patients on polytherapy (n=48) as shown in Table 3. On correlating serum levels of Vitamin D with duration of seizures a negative correlation was observed in all patients though the correlation was found to be statistically significant in polytherapy group (p<0.05) as shown in Table 4.

Discussion

Epilepsy is a major public health problem affecting majority of people worldwide. Treatment with AEDs is generally chronic, if not lifelong and may be associated with significant metabolic effects of people worldwide. Treatment with AEDs is generally chronic, if not lifelong and may be associated with significant metabolic effects. Hyperparathyroidism also has been suggested as a possible mechanism. Hyperparathyroidism can primarily activate bone resorption. Calcitonin deficiency is very common in the general population, it is difficult to demonstrate in vitro and in vivo [12,13]. As 25 (OH) D deficiency is very common in the general population, it is difficult to demonstrate that AED use specifically plays a role in the Vitamin D deficiency. In a study by Menon, it was observed that serum 25(OH) D levels declined from 29±1.3 to 17±2.1 ng/ml (P<0.001) within 6 months of initiation

Table 1. Demographic characteristics of patient’s according to the type of therapy

| Demographic characteristics | Patients on mono therapy | Patients on dual therapy | Patients on poly therapy |
|-----------------------------|--------------------------|--------------------------|-------------------------|
| Mean age                    | 23.58±8.5                | 23.6±8.6                 | 25.1±11.7               |
| Male/Female                 | 25/25                    | 32/18                    | 31/19                   |
| Duration of seizure <5 yrs | 36                       | 35                       | 18                      |
| 5-10 yrs                    | 14                       | 11                       | 30                      |
| >10 yrs                     | 0                        | 4                        | 2                       |
| Mean age of onset           | 19.44±6.8                | 18.88±6.10               | 19.22±10.9              |

Table 2. Laboratory characteristics of patient’s according to the type of therapy. *p<0.000

| Parameters                  | Patients on mono therapy | Patients on dual therapy | Patients on poly therapy |
|-----------------------------|--------------------------|--------------------------|-------------------------|
| S.Albumin                   | 4.5±0.26                 | 4.42±0.28                | 4.49±0.23               |
| S.Calcium                   | 9.2±0.42                 | 8.9±0.31                 | 8.0±0.22                |
| S.Phosphorus                | 4.46±0.96                | 4.47±0.68                | 4.26±0.43*              |
| Alkaline Phosphatase        | 109±322.4                | 121±91.3                 | 149.2±18.6*             |
| I.Ca ++                     | 1.04±0.13                | 1.03±0.12                | 1.02±0.11               |
| PTH                         | 27.2±60.0                | 48.5±18.9                | 72.69±6.93*             |
| Vitamin D                   | 16.81±16.34              | 14.9±4.79                | 10.66±4.65*             |

Table 3. Vitamin D status of patient’s according to the type of therapy

| Drug therapy | No. (%) of patients with 25(OH) vitamin D deficiency | No. (%) of patients with 25(OH) vitamin D insufficiency | No. (%) of patients with 25(OH) vitamin D insufficiency |
|--------------|------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Patients on mono therapy | 36 (72)                                                | 13 (26)                                                | 1 (2)                                                  |
| Patients on dual therapy  | 43 (86)                                                | 7 (14)                                                 | 0 (0)                                                  |
| Patients on poly therapy  | 48 (96)                                                | 2 (4)                                                  | 0 (0)                                                  |

Table 4. Correlation of vitamin D levels with duration of seizure in different therapy groups

| Therapy               | Mean duration of seizures | r value | p value |
|-----------------------|---------------------------|---------|---------|
| Mono therapy          | 3.85±2.24                 | -0.167  | 0.246   |
| Dual therapy          | 4.72±3.47                 | -0.155  | 0.282   |
| Poly therapy          | 5.86±2.31                 | -0.299  | 0.034   |
of AED therapy [14]. In another study by Krishnamurthy et al. It was observed that serum biochemical changes which may predispose the subjects to development of osteomalacia appear within 3 months of starting AED monotherapy. It suggested that simultaneous co-administration of calcium and 25(OH) D in recommended daily allowance dosage could be useful in limiting the changes in calcium and Vitamin D metabolism in patients on AEDs [15]. According to a study by Bartl et al. patients on long term treatment with AEDs have 2–3 fold risk of sustaining fractures. On an average, 50% of patients (ranging from 4% to 70% in different studies) have osteopathy. Bone loss has been noted with or even without evidence of Vitamin D deficiency among the enzyme-inducing drugs, especially phenytoin, phenobarbitone and carbamazepine [16].

We view the high prevalence of inadequate Vitamin D levels in epileptic patients as significant. Patients on polytherapy type of AED regimen are at a higher risk for low 25 (OH) D levels. Virtually all epileptic patients are at a risk for hypovitaminosis D. We could not screen our subjects with dual energy x-ray absorptiometry scans to evaluate bone mineral density. Therefore, we cannot comment on the impact of our patient’s low Vitamin D levels on their bone mineralisation. However, we postulate that 25(OH) D levels are associated with abnormal bone metabolism and the risk for poor bone health and increased fracture risk.

**Conclusion**

The present study emphasizes the need to create bone health awareness amongst epileptic patients and health care providers. Proper counselling regarding calcium and vitamin D intake, exposure to sunlight and physical activity is required. Further studies are needed to formulate clear guidelines on prophylactic Vitamin D supplementation needed for prevention and treatment of impaired bone metabolism in epilepsy.

**Conflicts of interest**

None

**References**

1. WHO (2001) Epilepsy: Aetiology, Epidemiology and Prognosis. Fact Sheet N°165; February, 2001. Available from: http://www.idealibrary.com. [Last accessed date 2018 Jun 21].
2. Amudhan S, Gurunj G, Sathishchandra P (2015) Epilepsy in India I: Epidemiology and public health. Ann Indian Acad Neurol 18: 263-277.
3. Fan HC, Lee HS, Chang KP, Lee YY, Lai HC, Hung PL et al. (2016) The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism. International journal of molecular sciences 17: 1242.
4. Lipuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20: 1131-1140.
5. Valmadrid C, Voorhees C, Litt B, Schneyer CR (2001) Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 58: 1369-1372.
6. Beluk A, Guzelipek M, Savli H, Temel I, Ozlik I, Kaygusuz A, et al. (2004) The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 50: 93-97.
7. Pack AM, Olarte LS, Morrell MJ, Fuster R, Resor SR, Shane E, et al. (2003) Bone mineral density in an outpatient population receiving enzyme inducing antiepileptic drugs. Epilepsy Behav 4: 169-174.
8. Sheth RD (2004) Metabolic concerns associated with antiepileptic medications. Neurology 63: S24- S29.
9. Pack AM, Gidal B, Vazquez B (2004) Bone disease associated with antiepileptic drugs. Cleve Clin J Med 71: S42- S48.
10. Pack AM, Morrell MJ (2001) Adverse effects of antiepileptic drugs on bone structure: Epidemiology, mechanisms and therapeutic implications. CNS Drugs 15: 633-642.
11. Koch HI, Kraft D, von Herrath D, Schaefer K (1972) Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 13: 829-834.
12. Vernillo AT, Ritkin BR, Hauschka PV (1990) Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 172.8 cells in culture. Bone 11: 309-312.
13. Kruse K, Suss A, Buuse M, Schneider P (1987) Monoclonal serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr 111: 57-63.
14. Menon B, Harinarayan CV (2010) The effect of anti-epileptic drug therapy on serum 25(OH) hydroxyvitamin D and parameters of calcium and bone metabolism - A longitudinal study. Seizure 19: 153-158.
15. Krishnamurthy G, Nair R, Sundar U, Kini P, Shirvastava M (2010) Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25(OH) hydroxy vitamin D at recommended daily allowance dosage: A prospective study. Neurol India 58: 213-219.
16. Bartl R (2007) Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment. Dtsch Med Wochenschr 132: 1475-1479.